Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/156079
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPiqué, Laia-
dc.contributor.authorMartínez de Paz, Alexia-
dc.contributor.authorPiñeyro, David-
dc.contributor.authorMartínez Cardús, Anna-
dc.contributor.authorCastro de Moura, Manuel-
dc.contributor.authorLlinàs-Arias, Pere-
dc.contributor.authorSetién, Fernando-
dc.contributor.authorGómez Miragaya, Jorge-
dc.contributor.authorGonzález Suárez, Eva-
dc.contributor.authorSigurdsson, Stefan-
dc.contributor.authorJonasson, Jon G.-
dc.contributor.authorVillanueva Garatachea, Alberto-
dc.contributor.authorVidal-Bel, August-
dc.contributor.authorDavalos, Veronica-
dc.contributor.authorEsteller, Manel-
dc.date.accessioned2020-04-20T13:45:10Z-
dc.date.available2020-04-20T13:45:10Z-
dc.date.issued2019-11-01-
dc.identifier.issn0950-9232-
dc.identifier.urihttp://hdl.handle.net/2445/156079-
dc.description.abstractHuman tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.-
dc.format.extent7 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMacmillan Publishers-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41388-019-0936-x-
dc.relation.ispartofOncogene, 2019, vol. 38, num. 45, p. 7106-7112-
dc.relation.urihttps://doi.org/10.1038/s41388-019-0936-x-
dc.rightscc-by (c) Piqué et al., 2019-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)-
dc.subject.classificationCàncer de mama-
dc.subject.classificationProteïnes-
dc.subject.classificationTeixit nerviós-
dc.subject.classificationADN-
dc.subject.classificationMetilació-
dc.subject.classificationRNA-
dc.subject.otherBreast cancer-
dc.subject.otherProteins-
dc.subject.otherNerve tissue-
dc.subject.otherDNA-
dc.subject.otherMethylation-
dc.subject.otherRNA-
dc.titleEpigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec694462-
dc.date.updated2020-04-20T13:45:10Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid31409895-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Ciències Fisiològiques)

Files in This Item:
File Description SizeFormat 
694462.pdf979.47 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons